| scholarly article | Q13442814 |
| P50 | author | Angelica Loskog | Q45864418 |
| Olle Korsgren | Q66144819 | ||
| P2093 | author name string | Magnus Essand | |
| Christina Ninalga | |||
| Helena Dzojic | |||
| Sofia Vikman | |||
| Thomas H Totterman | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| gene therapy | Q213901 | ||
| evasion of host immune response | Q1660157 | ||
| P304 | page(s) | 7200-7205 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor Microenvironment | |
| P478 | volume | 172 |
| Q37311057 | A novel immunotherapy for superficial bladder cancer by intravesical immobilization of GM-CSF. |
| Q33718737 | Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment |
| Q38026926 | AdCD40L--crossing the valley of death? |
| Q40098391 | Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy |
| Q37409025 | Adenoviral vector-based strategies for cancer therapy |
| Q39848254 | Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas |
| Q40313562 | Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. |
| Q26800814 | CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma |
| Q36112863 | CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. |
| Q35485418 | CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer |
| Q39951749 | CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1. |
| Q39028768 | CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes |
| Q40089815 | CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients |
| Q36447939 | Cancer and pregnancy share similar mechanisms of immunological escape |
| Q40263447 | Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy |
| Q40370712 | Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors |
| Q38694517 | Enhanced Mortality to Metastatic Bladder Cancer Cell Line MB49 in Vasoactive Intestinal Peptide Gene Knockout Mice |
| Q64259325 | Enhanced metastatic potential in the MB49 urothelial carcinoma model |
| Q39041608 | Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand |
| Q45875775 | Expression-targeted gene therapy for the treatment of transitional cell carcinoma |
| Q39984765 | Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. |
| Q26777403 | Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles |
| Q37945219 | Improving adenovirus based gene transfer: strategies to accomplish immune evasion |
| Q37163445 | Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy |
| Q37712742 | Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
| Q37564361 | Is cancer gene therapy an empty suit? |
| Q58748151 | Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy |
| Q38424907 | Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer |
| Q47804896 | Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma |
| Q38785200 | Template-driven gene selection procedure |
| Q64970828 | Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12. |
| Q28477188 | The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication |
| Q36249962 | The immunotherapy of prostate and bladder cancer. |
| Q37457728 | Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer |
Search more.